Avecho Biotechnology Limited (ASX: AVE) - Share Price

Current share price for AVE : $0.020 0.001 (4.76%)⁺

Avecho Biotechnology Limited (AVE) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It develops and commercialises innovative Human and Animal Health products using its proprietary drug delivery system called Tocopheryl Phosphate Mixture (TPM). TPM is derived from Vitamin E using unique, proprietary and patented processes and is proven to enhance the solubility and oral, dermal and transdermal absorption of drugs and nutrients.

AVE General Information ⁺

ASX Code	AVE
Website	N/A
Industry/Sector	Pharmaceuticals
Market Cap ($M)	77
AVE Share Price	$0.020
Day High	$0.021
Day Low	$0.020
Last Close	$0.021
AVE Share Price Movement	$0.00 ( 4.76% )

Prices as at 16:40, 25 Sep 2026

⁺Security prices are delayed by at least 20 minutes and are indicative only.

Avecho Biotechnology Limited (AVE) Upcoming Dividends & Yields

Distribution Type	Dividend	Franking	Ex-dividend date	Payment date	Current Price⁺	Price 7D Avg	Dividend Yield
Final	3¢	0%	22 Sep 2010	21 Oct 2010	-	-	-
Interim	2¢	0%	26 Feb 2010	24 Mar 2010	-	-	-
Final	2¢	0%	30 Sep 2009	21 Oct 2009	-	-	-

See all dividends from Avecho Biotechnology Limited (AVE) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Avecho Biotechnology Limited (AVE) price-sensitive announcements

AVE - Appendix 4D and Half-year Financial Report

Avecho Biotechnology Limited's Appendix 4D and Half-Year Financial Report for the period e

Avecho Biotechnology Limited (AVE)
26 Aug 2026 | 8:25 AM

AVE - June 2026 Quarterly Activities Report & Appendix 4C

Avecho Biotechnology Limited reported significant progress in its Phase III insomnia progr

Avecho Biotechnology Limited (AVE)
29 Jul 2026 | 9:43 AM

AVE - Positive interim results from Phase III insomnia program

Avecho Biotechnology Limited announced that the independent Data Monitoring Board (DMB) ha

Avecho Biotechnology Limited (AVE)
24 Jun 2026 | 8:50 AM

AVE - Trading Halt

Avecho Biotechnology Limited (ASX: AVE) has requested a trading halt of its securities on

Avecho Biotechnology Limited (AVE)
22 Jun 2026 | 8:31 AM

Avecho Biotechnology Limited (AVE) Recent ASX Announcements

Company	Sector	Market Cap ($m)	Headline	Release date/time⁺	Price at release⁺	Current price⁺	Gain/Loss
Avecho Biotechnology Limited (AVE) ORDINARY FULLY PAID	Health Care	$77	Avecho to present at the ASX SMIDcaps Conference	23 Sep 2026 9:01AM	$0.022	$0.020	fallen by 9.09%
Avecho Biotechnology Limited (AVE) ORDINARY FULLY PAID	Health Care	$77	Avecho enters final stage of Phase III insomnia trial	31 Aug 2026 9:15AM	$0.023	$0.020	fallen by 13.04%
Avecho Biotechnology Limited (AVE) ORDINARY FULLY PAID	Health Care	$77	Notification regarding unquoted securities - AVE	27 Aug 2026 4:53PM	$0.025	$0.020	fallen by 20%
Avecho Biotechnology Limited (AVE) ORDINARY FULLY PAID	Health Care	$77	Appendix 4D and Half-year Financial Report	26 Aug 2026 8:25AM	$0.021	$0.020	fallen by 4.76%
Avecho Biotechnology Limited (AVE) ORDINARY FULLY PAID	Health Care	$77	Avecho strengthens BD capability with senior appointment	24 Aug 2026 9:54AM	$0.021	$0.020	fallen by 4.76%
Avecho Biotechnology Limited (AVE) ORDINARY FULLY PAID	Health Care	$77	Small Holding Share Sale Facility Completion	12 Aug 2026 10:02AM	$0.021	$0.020	fallen by 4.76%

AVE Financial Summary

Year to Dec	NPAT	EPS	EPS chg (%)	Yield (%)	Franking (%)
2025A	-$4.42	-$0.10	40.00%	0.00%	0.0%
2024A	-$3.12	-$0.10	-28.60%	0.00%	0.0%
2023A	-$3.07	-$0.10	7.70%	0.00%	0.0%

AVE Peer Comparison

Company	Mkt Cap	EPS Growth (%)			P/E (%)			Dividend Yield (%)
Company	Mkt Cap	2023 A	2024 A	2025 A	2023 A	2024 A	2025 A	2023 A	2024 A	2025 A
Avecho Biotechnology Limited (AVE)	$81M	0.4000	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Clarity Pharmaceuticals Ltd (CU6)	$780M	0.4454	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Neuren Pharmaceuticals Limited (NEU)	$2,612M	-0.7857	0.2462	0.9655	88.5260	71.0345	36.1404	0.00%	1.60%	1.89%

AVE Directors

Name	Position	Start Date
Dr Gregory (Greg) Collier	Non-Executive Chairman, Non-Executive Director	13 Apr 2015
Dr Ross Murdoch	Non-Executive Director	13 Apr 2015
Ms Katherine(Kathy) Ellen Danielle Connell	Non-Executive Director	26 Apr 2024

Avecho Biotechnology Limited (AVE) Changes in Directors' Interest & Trades

Date of change	Director	Buy/Sell	Security Type	Qty	Trade Price	Value
6 May 2026	COLLIER, Gregory (Greg)	Exercise	Options	800,000	$0.012	$9,600.000
6 May 2026	COLLIER, Gregory (Greg)	Issued	Indirect Shares	800,000	$0.012	$9,600.000
22 Nov 2023	MCNAMARA, Matthew	Issued	Indirect Shares	1,666,666	$0.006	$9,999.996

See all changes in directors' interest & trades for Avecho Biotechnology Limited (AVE) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

AVE Management

Name	Position
Paul Gavin	Chief Executive Officer
Roksan Libinaki	Chief Operating Officer
Naomi Lawrie	Company Secretary

AVE Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Avecho Biotechnology Limited (AVE). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding	Name
349,133,188 (9.50%)	Mark Gregory KERR

AVE Calendar of Events

Date	Event
25 August 2027	Report (Interim)
26 February 2027	Report (Annual)
26 February 2027	Report (Prelim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.

What our members say about us